Drug Shortage Report for ADACEL

Last updated on 2026-03-12

Report ID 280445
Drug Identification Number 02240255
Brand name ADACEL
Common or Proper name Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed
Company Name SANOFI VACCINES CANADA LTD.
Market Status MARKETED
Active Ingredient(s) TETANUS TOXOID FIMBRIAE TYPES 2 AND 3 PERTACTIN FILAMENTOUS HAEMAGGLUTININ DIPHTHERIA TOXOID PERTUSSIS TOXOID
Strength(s) 5LF 5MCG 3MCG 5MCG 2LF 2.5MCG
Dosage form(s) SUSPENSION
Route of administration INTRAMUSCULAR INTRAMUSCULAR
Packaging size 10 x 0.5 mL vials
Anatomical Therapeutical Chemical (ATC) code J07AJ
Anatomical Therapeutical Chemical (ATC) description BACTERIAL VACCINES
Reason for shortage Other (Please describe in comments)
Anticipated start date 2026-03-10
Actual start date 2026-03-10
Estimated end date 2026-04-24
Actual end date
Shortage status Actual shortage
Updated date 2026-03-12
Company comments A supplier has identified a defect potentially impacting batches of Adacel intended for release to the Canadian market. Sanofi is working to resolve the situation as soon as possible, and identify options to mitigate any potential impact.
Health Canada comments
Tier 3 Status No
Contact Address 1755 STEELES AVENUE WEST
TORONTO, ONTARIO
CANADA M2R 3T4
Company contact information Customer Service/Service à la clientèle: 1-800-268-4171 Vaccine Information Service/Service d'information sur les vaccins: 416-667-2611 or 1-888-621-1146

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v2 2026-03-12 French Compare
v1 2026-03-12 English Compare

Showing 1 to 2 of 2